BioLight Life Sciences Investments invests in, manages and commercializes biomedical innovations grouped into "clusters" around defined medical conditions. Its two current clusters are in ophthalmology via 100% ownership of XLVision Sciences and in cancer diagnostics via a 31.24% controlling ownership of Micromedic (MCTC.TA). XLVision technologies include IOPtiMate(TM), a laser-based noninvasive surgical treatment for glaucoma; TeaRx, a point-of-care dry-eye syndrome diagnostic test; and Eye-D(TM), a long-term controlled release drug-delivery implant platform. Micromedic diagnostic tests are designed to detect colorectal, cervical, breast, bladder, lung and other cancers. Leading key investors, holding about 45% of BioLight`s shares, are Mr. Israel Makov, Chairman of Sun Pharmaceuticals, former CEO and President of Teva Pharmaceuticals and former Chairman of Given Imaging, Mr. Dilip Shanghvi, founder of Sun Pharmaceuticals, India`s largest pharmaceutical company, and Mr. Dan Oren, founder and CEO of Dexcel Pharma, the second-largest pharmaceutical manufacturer in Israel. An additional 20% of the company`s shares are held by 3 reputable institutional investors.
For more information please visit the Company`s website at
Itai Bar-Natan, CFO
At present BioLight has two clusters that focuse on Cancer Diagnostics and ophthalmic diseases. Additional clusters are in development at various planning stages.
Micromedic is a publicly traded company listed on the Tel Aviv Stock Exchange. The Company focuses, through its investee companies, on the development and commercialization of novel molecular biomarkers related to cancer, including early detection of disease, genetic risk and optimization of treatment modalities (personalized medicine).
Read more >>
XLVision is BioLight’s wholly owned ophthalmic cluster.
XLVision currently has three technologies: a commercial laser-based device used to reduce intraocular pressure through glaucoma surgery without penetrating the eyeball; a multi-parameter, easy-to-read test to detect, select treatment and monitor dry eye syndrome and a long-term controlled-release drug-delivery implant platform with a first indication containing latanaprost, the most prescribed glaucoma drug.